282 related articles for article (PubMed ID: 23814490)
41. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
42. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
44. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
[TBL] [Abstract][Full Text] [Related]
45. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.
Shang J; Yang F; Wang Y; Wang Y; Xue G; Mei Q; Wang F; Sun S
J Cell Biochem; 2014 Apr; 115(4):772-84. PubMed ID: 24249161
[TBL] [Abstract][Full Text] [Related]
47. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
48. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
49. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
50. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
[TBL] [Abstract][Full Text] [Related]
51. TAB3 upregulates PIM1 expression by directly activating the TAK1-STAT3 complex to promote colorectal cancer growth.
Li Q; Chen L; Luo C; ChenYan ; Ge J; Zhu Z; Wang K; Yu X; Lei J; Liu T; Peng X; Liu X; Yuan R
Exp Cell Res; 2020 Jun; 391(1):111975. PubMed ID: 32229191
[TBL] [Abstract][Full Text] [Related]
52. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.
Liu Z; He W; Gao J; Luo J; Huang X; Gao C
Oncotarget; 2015 Apr; 6(10):8019-35. PubMed ID: 25749522
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects.
Rathi A; Kumar D; Hasan GM; Haque MM; Hassan MI
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129995. PubMed ID: 34455019
[TBL] [Abstract][Full Text] [Related]
54. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
55. U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma.
Weirauch U; Grünweller A; Cuellar L; Hartmann RK; Aigner A
Nucleic Acid Ther; 2013 Aug; 23(4):264-72. PubMed ID: 23724780
[TBL] [Abstract][Full Text] [Related]
56. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
[TBL] [Abstract][Full Text] [Related]
57. microRNA-206 is involved in survival of hypoxia preconditioned mesenchymal stem cells through targeting Pim-1 kinase.
Zhang Y; Lei W; Yan W; Li X; Wang X; Zhao Z; Hui J; Shen Z; Yang J
Stem Cell Res Ther; 2016 Apr; 7(1):61. PubMed ID: 27103465
[TBL] [Abstract][Full Text] [Related]
58. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.
Andina N; Didichenko S; Schmidt-Mende J; Dahinden CA; Simon HU
J Allergy Clin Immunol; 2009 Mar; 123(3):603-11. PubMed ID: 19152965
[TBL] [Abstract][Full Text] [Related]
59. miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis.
Zhao C; Zhao Q; Zhang C; Wang G; Yao Y; Huang X; Zhan F; Zhu Y; Shi J; Chen J; Yan F; Zhang Y
Sci Rep; 2017 Jun; 7(1):4194. PubMed ID: 28646148
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
